Hepatoma Recurrence After Radiofrequency Ablation (RFA) In Egyptian Patients With HCV | 51474
Journal of Gastrointestinal & Digestive System
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Radiofrequency ablation (RFA) is the treatment of choice for patients with an early-stage Hepatocellular Carcinoma (HCC)
who are not candidates for surgical management; however, it is associated with a recurrence rate as high as 15–30% after
one year. The aim of this study was to analyze the risk factors for HCC recurrence in Egyptian patients after RFA. This study
was conducted on 45 HCC patients presented at two large referral centers for management of HCC in Egypt. Only patients with
an early-stage HCC, eligible for RFA, were included in the analysis and were followed up for a period of one year and grouped
into 2 groups: Group I which included patients with HCC recurrence during follow-up (n=30) and Group II with patients who
did not show any recurrence during follow-up (n=15). The risk factors associated with recurrence included smoking (70% in
Group I vs. 40% in Group II), hepatomegaly (50% in Group I vs. 40% in Group II), splenomegaly (90% in Group I vs. 53.3% in
Group II), heterogeneous liver (30% in Group I vs. 6.66% in Group II), bilobar involvement (20% in Group I vs. 6.66% in Group
II), and tumors in contact with hepatic capsule (20% in Group I vs. 6.66% in Group II). Hepatomegaly, liver heterogeneity,
and splenomegaly (a sign of portal hypertension) together with the tumor factors such as large size, bilobar involvement, and
proximity to liver capsule were the factors that showed a significant association with tumor recurrence in this study.
Eslam Ahmed Habba is an Assistant Lecturer of Hepatology, Gastroenterology and Infectious Diseases at Tropical Medicine department, Faculty of Medicine, Tanta University Hospitals, Egypt. He is an active member of European Association for the Study of Liver (EASL). Also, he is a member of American Association for Study of Liver Diseases (AASLD) and a member of Liver Tumors Committee at new Tanta University Teaching Hospital. He has some published papers in the field of Hepatology and Infections. Recently, he had a published book about Hepatocellular Carcinoma.